Stay updated on Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2, indicating a minor maintenance update. No substantive changes to study details, eligibility criteria, or outcomes are apparent from the provided context.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1; this change does not alter any study details, eligibility criteria, outcomes, or locations.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a glossary toggle label and minor UI text tweaks. Updated the revision string from v3.3.4 to v3.4.0 and corrected capitalization of QC-related fields (No FEAR Act data).SummaryDifference0.2%

- Check62 days agoChange DetectedNew revision entries appear for 2026-01-08, 2025-12-16, and 2025-12 with version v3.3.4, while older revisions including 2025-09-18, 2025-09-16, 2025-03 and v3.3.3 were removed.SummaryDifference0.3%

- Check83 days agoChange DetectedAdded a Locations section highlighting Massachusetts study sites (Boston) and updated the page revision to v3.3.3. The previous Massachusetts Locations grouping and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

Stay in the know with updates to Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.